化学
癌症
铱
癌细胞
铼
细胞凋亡
选择性
组合化学
癌症治疗
癌症研究
钌
体内
铑
体外
药品
癌细胞系
药理学
生物化学
内科学
有机化学
医学
生物技术
生物
催化作用
作者
Sourav De,Sabnaz Kazi,Sabyasachi Banerjee,Subhasis Banerjee,Nandan Sarkar,Suraj Kumar Shah,Yung‐Chih Kuo,S.K. Ashok Kumar
标识
DOI:10.1016/j.ccr.2023.215462
摘要
It is one of the challenging works to deal with second major cause of death due to cancer and to reduce the mortality rate caused by this. Researchers have been finding various approaches to minimise the unwanted effect of cancer therapy and increase the selectivity of the cancer cells that are cancerous without harming the normal cells. Accordingly, they have discovered and reported a series of anti-cancer complexes with moderate to high selective behaviour. Conventional cancer therapies are resistant to some of standard drugs. When we consider the group of metallotherapeutic anticancer agents, platinum (Pt) based anti-neoplastic complexes have some drawbacks and lower potency and selectivity than complexes like Ruthenium (Ru), Iridium (Ir), Rhodium (Rh) and Rhenium (Re) towards various cancer cell lines (in vitro). Many of them have proved the in vivo applications. This review aims to provide a comprehensive summary of prior literature pertaining to the cytotoxic impact and cellular uptake of those metallocomplexes (Ru, Ir, Rh and Re), with particular emphasis on recently developed metal-based complexes. Most of them target the DNA, mitochondria, and induces cancer cell apoptosis lowering the adverse drug reaction.
科研通智能强力驱动
Strongly Powered by AbleSci AI